Atlas

Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

Where to Find FDA 483 Reports (and How to Read One)
FeaturedFDA Form 483s

Where to Find FDA 483 Reports (and How to Read One)

There are three routes to an FDA Form 483: FDA's FOIA electronic reading room, a FOIA request, or a searchable database. This guide compares them on coverage, wait time and search, then explains how to read a 483 once you have it, with three recent examples.

Read article

Editor’s Picks

Preparing for FDA Pre-Approval Inspections: A Practical Guide
Inspection Readiness

Preparing for FDA Pre-Approval Inspections: A Practical Guide

FDA Inspection Classifications: VAI, NAI, and OAI Explained
Inspection Readiness

NAI, VAI, OAI: What Each FDA Inspection Classification Means

Preparing for FDA QSIT Inspections: What to Expect
Medical Devices

Preparing for FDA QSIT Inspections: What to Expect

How to Navigate the FDA Warning Letters Database Successfully
Warning Letters & Enforcement

FDA Warning Letter Database: How to Search It and Trace a Letter to Its 483

Atlas cover for 21 CFR Part 803: medical device reporting deadlines for manufacturers, importers and user facilities, with 2,231 of 10,321 device Form 483s citing Part 803.
Medical Devices

21 CFR Part 803: medical device reporting rules, deadlines, and what FDA cites

21 CFR Part 803, FDA's medical device reporting (MDR) regulation, explained section by section: who must report, what counts as a reportable event, the 30-day, 5-day and 10-work-day deadlines, eMDR submission, MDR procedures and event files. Atlas Form 483 data shows which Part 803 sections FDA investigators cite at device facilities, how often, and how the share has moved since 2013, with named Form 483 examples.

Read more
Bioburden testing cover: pre-filtration and per-device limits, ISO 11737-1, and the contamination citations behind 129 FDA drug inspections, 50.4% of them ending OAI, and 56 device inspections, January 2025 to October 2026.
CAPA & Quality Systems

Bioburden testing: limits, ISO 11737 and what FDA cites

What bioburden is, how drug manufacturers test it before sterile filtration and terminal sterilization under 21 CFR 211.113, how device manufacturers measure it per device under ISO 11737-1 and use it to set the sterilization dose, what limits apply, and how often FDA cited contamination and sterilization controls at 774 Part 211 drug inspections and 1,124 device inspections that closed January 2025 to October 2026, with named Form 483 examples.

Read more
Endotoxin testing cover: LAL, rFC and what FDA cites, with 98 of 774 Part 211 drug inspections citing sterile process controls under 21 CFR 211.113(b) and 54.1% of those ending OAI, January 2025 to September 2026.
CAPA & Quality Systems

Endotoxin testing: LAL methods, rFC, the K/M limit and what FDA cites

What endotoxin testing is, how the bacterial endotoxins test (USP 85, Ph. Eur. 2.6.14) works with gel clot, turbidimetric and chromogenic LAL methods, where recombinant factor C and recombinant cascade reagents stand under USP 86 and Ph. Eur. 2.6.32, how the K/M endotoxin limit and the maximum valid dilution are calculated, FDA's device limits from its March 2026 questions and answers guidance, and how FDA cited endotoxin and sterile process controls at 774 Part 211 drug inspections from January 2025 to September 2026.

Read more
IQ OQ PQ cover: equipment qualification explained, with 383 of 774 Part 211 drug inspections citing equipment design, maintenance or calibration and 33.7% of those ending OAI, January 2025 to September 2026.
CAPA & Quality Systems

IQ OQ PQ: what each equipment qualification proves, and what FDA cites

What installation, operational and performance qualification (IQ, OQ, PQ) each prove, where design qualification and FAT/SAT fit, what a qualification protocol contains, how qualification differs from validation, and how often FDA cites equipment design, maintenance and calibration (21 CFR 211.63, 211.67, 211.68) on drug Form 483s, with device equivalents, from 774 Part 211 drug inspections that closed January 2025 to September 2026.

Read more
QMSR for device teams: 349 FDA device Form 483s from 131 investigators between February 2 and July 17, 2026, with risk management wording on 31.5% of them.
Medical Devices

QMSR: what FDA's Quality Management System Regulation changed for device teams in 2026

The QMSR, FDA's Quality Management System Regulation, replaced the Quality System Regulation for medical devices on February 2, 2026. This guide covers what changed in day-to-day practice: the new names for design, device and batch records, management review and audit reports that investigators can now read, Compliance Program 7382.850 in place of QSIT, and what a device team should do now. It adds Atlas data on the first months: 349 device Form 483s from 131 investigators, the January 2026 inspection dip, and the wording FDA uses on management review and internal audit citations.

Read more
What happens during an FDA inspection, step by step: drug inspections that end in a Form 483 last a median of 5 days, and the EIR arrives a median of 77 days later.
Inspection Readiness

What happens during an FDA inspection: the process, step by step

The FDA inspection process step by step: the Form FDA 482, opening meeting, floor tour, records review, daily debriefs, the Form 483 closeout and the NAI, VAI or OAI classification. With Atlas data on inspection length from 2,245 facility records, investigator team size and observations per Form 483, and FDA classification data on 35,021 inspections ending January 2025 to October 2026, including the median 77 days from a drug inspection's end to EIR release.

Read more
503A compounding pharmacy cover: what section 503A requires and what 280 FDA Form 483s at 204 compounding pharmacies cite, with environmental monitoring on 33% of forms, 2009 to April 2026.
Warning Letters & Enforcement

503A compounding pharmacy: the FDA rules and what 280 Form 483s cite

A 503A compounding pharmacy is a state-licensed pharmacy that compounds drugs for identified patients under section 503A of the FD&C Act. This guide covers the seven statutory conditions, the bulk drug substance and ingredient sourcing rules, the copies limit, the health system common ownership policy, when FDA inspects a 503A pharmacy, and the Atlas Form 483 record for 204 compounding pharmacies: 280 forms and 1,967 observations from 2009 to April 2026.

Read more
Bachem FDA inspection history: 37 FDA inspections at Torrance, Vista, Bubendorf and Vionnaz, 16 ending in a Form 483, with both May 2026 US inspections classified VAI.
Company Inspection Histories

Bachem FDA inspection history: Torrance, Vista and every Form 483

The FDA inspection record of Bachem, the peptide and oligonucleotide manufacturer: four facility records in California and Switzerland, 37 inspections from 2001 to 2026, 16 ending with a Form 483. Each facility's history, the two May 2026 inspections at Torrance and Vista and their VAI classifications, what the one public Form 483 cites, the investigators on the record, and what a supplier file on Bachem should hold.

Read more
Media fill test cover: 46 sterile process validation citations on FDA Form 483s, with 54.1% of inspections citing aseptic rules ending OAI against 23.0% of the rest, January 2025 to October 2026.
Inspection Readiness

Media fill test: frequency, run size, acceptance criteria, and what FDA cites

What a media fill test (aseptic process simulation) is, how often to run one, how many units to fill, how long and at what temperature to incubate, the FDA 2004 and EU Annex 1 acceptance criteria side by side, which interventions to simulate, what happens after a failure, and how often FDA cited aseptic processing failures on Form 483s at 774 drug inspections from January 2025 to October 2026.

Read more
Torrent Pharmaceuticals FDA inspection history cover: 24 of 40 FDA inspections across eight Torrent facilities ended with a Form 483, with the 2019 Indrad warning letter closed out on September 4, 2024.
Company Inspection Histories

Torrent Pharmaceuticals FDA inspection history: Indrad, Dahej and every Form 483

The FDA inspection record of Torrent Pharmaceuticals: eight Torrent facility records in India and the US, 40 inspections and 24 ending with a Form 483. What the 2019 Indrad warning letter cited, how the Indrad, Dahej, Pithampur, Visakhapatnam and Bileshwarpura records read facility by facility, the citations FDA repeats across the group, and where each facility stands in November 2026.

Read more
BLA vs NDA vs ANDA cover: the facility gate each FDA application triggers, with 42 of 65 complete response letters in 2024 citing facilities and BLAs drawing 42% of published letters in 2025.
FDA Databases & Guidance

BLA vs NDA: the differences, plus ANDA, 505(b)(2) and biosimilars, and the inspection each one triggers

A comparison of the five FDA marketing application pathways (NDA, 505(b)(2), ANDA, BLA and 351(k) biosimilar) by statute, reviewing center, data required, exclusivity, user fee program and review goal, followed by the part most explainers skip: the pre-approval or pre-license inspection each pathway triggers. Includes Atlas counts of complete response letters by application type (65 in 2024, 48 in 2025, 17 in early 2026), drug vs biologic inspection outcomes from January 2025 to October 2026, and a June 2026 Form 483 at a licensed vaccine maker.

Read more
PDUFA date cover: how FDA sets the goal date (10 months standard, 6 months priority from filing) and why 42 of 65 complete response letters in 2024 cited facility inspections
FDA Databases & Guidance

PDUFA date: how FDA sets the goal date, what moves it, and why facilities miss it

A guide to PDUFA goal dates as of November 2026: what a PDUFA date is, how FDA sets it under the PDUFA VII commitment letter (10 months standard and 6 months priority, counted from the 60-day filing date for NME NDAs and original BLAs), what extends it (major amendments, unlisted facilities), where facility inspections sit on the review clock, and why facility problems appeared in 42 of the 65 complete response letters FDA issued in 2024. Includes Atlas inspection outcome data for drug quality and bioresearch monitoring inspections and a dated table of PDUFA dates sponsors announced for late 2026.

Read more
Release testing in pharma cover: 21 CFR 211.165 cited at 102 of 774 Part 211 drug inspections, with 59.8% of those ending OAI against 22.5% without the citation
CAPA & Quality Systems

Release testing in pharma: what 21 CFR 211.165 requires and what FDA cites

What release testing in pharma means under 21 CFR 211.165 (laboratory testing of every batch against final specifications, microbiological testing, written sampling plans, statistical acceptance criteria, validated methods and rejection of failing batches), how it connects to the 211.192 record review and the quality unit's release decision, how EU Qualified Person certification differs, and what FDA wrote in 109 Form 483 observations at 102 drug inspections from January 2025 to September 2026.

Read more